Equities research analysts expect Stryker Corporation (NYSE:SYK) to report $2.97 billion in sales for the current quarter, Zacks reports. Ten analysts have provided estimates for Stryker Corporation’s earnings. The lowest sales estimate is $2.95 billion and the highest is $3.00 billion. Stryker Corporation posted sales of $2.83 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 4.9%. The business is scheduled to issue its next earnings results after the market closes on Thursday, October 26th.

According to Zacks, analysts expect that Stryker Corporation will report full-year sales of $2.97 billion for the current financial year, with estimates ranging from $12.23 billion to $12.34 billion. For the next year, analysts expect that the company will report sales of $13.14 billion per share, with estimates ranging from $12.96 billion to $13.24 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Stryker Corporation.

Stryker Corporation (NYSE:SYK) last released its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. During the same period last year, the business earned $1.39 earnings per share. Stryker Corporation’s revenue was up 6.1% compared to the same quarter last year.

Several analysts have recently issued reports on SYK shares. SunTrust Banks, Inc. restated a “buy” rating and issued a $161.00 price objective on shares of Stryker Corporation in a research report on Monday. Royal Bank Of Canada reaffirmed a “buy” rating and set a $155.00 price objective on shares of Stryker Corporation in a research note on Friday, September 1st. Argus reiterated a “buy” rating and set a $160.00 price objective on shares of Stryker Corporation in a research report on Tuesday, August 29th. BidaskClub cut Stryker Corporation from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. Finally, Needham & Company LLC raised shares of Stryker Corporation from an “underperform” rating to a “hold” rating in a research note on Friday, August 25th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. Stryker Corporation currently has an average rating of “Hold” and a consensus price target of $146.78.

ILLEGAL ACTIVITY WARNING: “Stryker Corporation (SYK) Expected to Announce Quarterly Sales of $2.97 Billion” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/stryker-corporation-syk-expected-to-announce-quarterly-sales-of-2-97-billion/1602349.html.

In related news, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the sale, the insider now directly owns 8,983 shares of the company’s stock, valued at approximately $1,313,853.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Floyd sold 19,305 shares of the company’s stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total transaction of $2,790,730.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,429 shares of company stock worth $3,686,927. 7.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of SYK. Acrospire Investment Management LLC purchased a new stake in shares of Stryker Corporation during the 2nd quarter valued at about $111,000. Bollard Group LLC lifted its position in Stryker Corporation by 0.4% during the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 3 shares in the last quarter. Motco lifted its position in Stryker Corporation by 50.7% during the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 278 shares in the last quarter. Bruderman Asset Management LLC acquired a new position in Stryker Corporation during the 2nd quarter worth approximately $150,000. Finally, James Investment Research Inc. acquired a new position in Stryker Corporation during the 2nd quarter worth approximately $155,000. 74.13% of the stock is owned by institutional investors.

Stryker Corporation (SYK) opened at 142.02 on Monday. The firm has a 50-day moving average of $143.56 and a 200 day moving average of $138.98. The firm has a market capitalization of $53.12 billion, a price-to-earnings ratio of 31.70 and a beta of 0.81. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $148.84.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date is Thursday, September 28th. Stryker Corporation’s dividend payout ratio (DPR) is presently 37.95%.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Get a free copy of the Zacks research report on Stryker Corporation (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.